Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: May 20, 2011

Premium

Vermillion this week appointed Bruce Huebner to its board of directors.

Currently Huebner is managing director at the healthcare consulting firm LynxCom Partners. Previously he was president and CEO of microarray company Nanogen, and before that he was executive vice president and chief operating officer of Gen-Probe.


Stacey Sias has left her positions at Celera as senior VP of business development and strategic planning and as an executive director, the company said in a recent filing with the US Securities and Exchange Commission.

Sias previously was VP of licensing at Roche Molecular Systems, she was a molecular biologist at Codon and Genentech, and she is a registered patent agent with the US Patent and Trademark Office.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.